Literature DB >> 15008720

Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort.

M el-Geneidy1, M Garzotto, I Panagiotou, Y C Hsieh, M Mori, L Peters, T Klein, T M Beer.   

Abstract

OBJECTIVE: To identify predictors of delayed therapy with curative intent, an increasingly common option in contemporary patients with prostate cancer who initially choose watchful waiting. PATIENTS AND METHODS: The characteristics of all patients at one institution and diagnosed with T1-4NXM0 prostate cancer between 1993 and 2000 were prospectively recorded. Factors recorded included: age, tumour stage, histological type, Gleason score, serum prostate specific antigen (PSA) level, prostate volume, PSA density (PSAD), percentage of positive biopsy cores, and the initial treatment selection. Outcomes, including all cancer-directed interventions, all serum PSA values, and initial outcomes of all interventions with curative intent, were determined by review of all medical records and cancer registry data.
RESULTS: Of 187 patients on watchful waiting, 175 had stage T1 or T2 cancer and were analysed primarily. Thirty-eight (22%) of these patients received delayed intervention with curative intent (15 radical prostatectomy, 17 external beam radiotherapy, six brachytherapy). Age (P < 0.001) and percentage of positive biopsy cores (P = 0.042) were significant independent predictors of intervention with curative intent. When the PSA doubling time was added to the model it became a significant predictor (P = 0.018), with percentage positive biopsy cores (P = 0.022) and age (P < 0.001).
CONCLUSIONS: Therapy with curative intent is common in contemporary patients with prostate cancer who initially choose watchful waiting. Age and percentage positive biopsy cores are independent predictors of such intervention, with PSA doubling time also an independent predictor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15008720     DOI: 10.1111/j.1464-410x.2003.04669.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  6 in total

1.  Quality of life in men undergoing active surveillance for localized prostate cancer.

Authors:  Jonathan Bergman; Mark S Litwin
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

2.  Risk stratification of men choosing surveillance for low risk prostate cancer.

Authors:  Kenneth S Tseng; Patricia Landis; Jonathan I Epstein; Bruce J Trock; H Ballentine Carter
Journal:  J Urol       Date:  2010-03-20       Impact factor: 7.450

Review 3.  Low risk prostate cancer in men under age 65: the case for definitive treatment.

Authors:  Thomas L Jang; Ofer Yossepowitch; Fernando J Bianco; Peter T Scardino
Journal:  Urol Oncol       Date:  2007 Nov-Dec       Impact factor: 3.498

4.  Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience.

Authors:  H Ballentine Carter; Anna Kettermann; Christopher Warlick; E Jeffrey Metter; Patricia Landis; Patrick C Walsh; Jonathan I Epstein
Journal:  J Urol       Date:  2007-10-22       Impact factor: 7.450

5.  Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort.

Authors:  William V Shappley; Stacey A Kenfield; Julie L Kasperzyk; Weiliang Qiu; Meir J Stampfer; Martin G Sanda; June M Chan
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

Review 6.  Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era.

Authors:  Richard M Martin; David Gunnell; Freddie Hamdy; David Neal; Athene Lane; Jenny Donovan
Journal:  J Urol       Date:  2006-08       Impact factor: 7.450

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.